Dept. of Endodontics, the Affiliated Stomatological Hospital of Nanjing Medical University, Nanjing 210029, China.
State Key Laboratory Cultivation Base of Research, Prevention and Treatment for Oral Diseases, Nanjing 210029, China.
Hua Xi Kou Qiang Yi Xue Za Zhi. 2024 Oct 1;42(5):572-580. doi: 10.7518/hxkq.2024075.
This study aimed to explore the effects of bone morphogenetic protein 2 (BMP-2) encapsula-ted in poly(lactic-co-glycolic acid) (PLGA) microcapsules with different molecular weights on the osteogenic ability of osteoblasts.
PLGA microcapsules with different molecular weights (12 000, 30 000) encapsulating BMP-2, were prepared using a dual-channel microinjection pump. The morphology and structure of the microcapsules were characterized by optical microscopy and scanning electron microscopy. The sustained-release performance of the microcapsules was characterized by phosphate buffered saline immersion method. The cell compatibility of the microcapsules was detected by the Calcein-AM/PI staining and CCK-8 method. The chemotactic effect of BMP-2-encapsulated microcapsules on MC3T3-E1 cells after 48 h of treatment was detected by the Transwell assay. The alkaline phosphatase activity assay and Alizarin Red S staining were used to characterize the effect of microcapsules on the osteogenic ability of MC3T3-E1 cells.
Both types of microcapsules with different molecular weights exhibited smooth surfaces, as well as uniform and good cell compatibility. The chemotactic effect of the 12 000 microcapsules was outstanding. The 30 000 microcapsules had a longer sustained-release time, and the initial burst release was reduced by approximately 25% compared with the 12 000 microcapsules. In addition, 30 000 microcapsules performed better in long-term osteogenesis induction than 12 000 microcapsules.
In this study, the release of BMP-2 is regulated by adjusting the molecular weight of PLGA, and the results indicate that 30 000 microcapsules can better induce the long-term osteogenic ability of MC3T3-E1 cells.
本研究旨在探讨不同分子量的聚乳酸-羟基乙酸共聚物(PLGA)微胶囊包裹骨形态发生蛋白 2(BMP-2)对成骨细胞成骨能力的影响。
采用双通道微量注射泵制备不同分子量(12000、30000)的 PLGA 微胶囊包裹 BMP-2。采用光学显微镜和扫描电子显微镜观察微胶囊的形态和结构。采用磷酸盐缓冲液浸泡法研究微胶囊的缓释性能。采用 Calcein-AM/PI 染色和 CCK-8 法检测微胶囊的细胞相容性。采用 Transwell 检测 BMP-2 包裹微胶囊对 MC3T3-E1 细胞的趋化作用。采用碱性磷酸酶活性测定和茜素红 S 染色法评价微胶囊对 MC3T3-E1 细胞成骨能力的影响。
两种不同分子量的微胶囊均表现出光滑的表面,具有均匀良好的细胞相容性。12000 微胶囊的趋化作用较为显著。30000 微胶囊具有较长的缓释时间,与 12000 微胶囊相比,初始突释减少了约 25%。此外,30000 微胶囊在长期成骨诱导方面优于 12000 微胶囊。
本研究通过调节 PLGA 的分子量来调控 BMP-2 的释放,结果表明 30000 微胶囊能更好地诱导 MC3T3-E1 细胞的长期成骨能力。